| Literature DB >> 34262304 |
Mingbiao Ma1,2,3, Minjun Chu1,2, Lvyan Tao3,4,5, Jue Li1,2, Xiaojuan Li1,2, Hailin Huang1,2, Kexuan Qu6, Haiping Wang1,2, Li Li3,4,5, Tingyi Du1,2,3.
Abstract
PURPOSE: The present study investigated the prevalence characteristics of oxacillin susceptible mecA-positive Staphylococcus aureus (OS-MRSA) in a children's hospital in Kunming from January 2019 to December 2020.Entities:
Keywords: MRSA; OS-MRSA; Staphylococcus aureus; children; oxacillin
Year: 2021 PMID: 34262304 PMCID: PMC8275014 DOI: 10.2147/IDR.S317670
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
The Main Primers Used for PCR Amplification in the Study
| Gene | Primer Sequence (5ʹ-3ʹ) | Amplicon Size (bp) | Tm (°C) |
|---|---|---|---|
| F: TCCAGATTACAACTTCACCAGG | 162 | 59 | |
| R: CCACTTCATATCTTGTAACG | |||
| F: GAAAAAAAGGCTTAGAACGCCTC | 138 | 59 | |
| R: GAAGATCTTTTCCGTTTTCAGC | |||
| F: TTATCAATGTGCGGGTGG | 219 | 54 | |
| R: TTTCCTGTAAATAACGTCTTGC | |||
| F: ACTGAGCATAATGGAAACCAA | 250 | 54 | |
| R: GCATCATGTCATACCAAAAGC | |||
| F: CTGATTACTATCCAAGAAATTCGATTG | 210 | 57 | |
| R: CTTTCCAGCCTACTTTTTTATCAGT | |||
| F: TACGTGGCAAACTGGTCAA | 561 | 57 | |
| R: AGCACTGAGTCCAAGGAAACTA | |||
| F: GCATTTAGTTTAGCGGCAGTAG | 255 | 57 | |
| R: TAATTGGTGGCACTTTAGCAG | |||
| F: CGAAGAAAGTAGCGGTAAAGTAAG | 482 | 57 | |
| R: GTTCTGGATCTGGCGTTGG | |||
| F: ATCATTAGGTAAAATGTCTGGACATGATCC | 430 | 54 | |
| R: CATCAACTGTATTGGACATGATCCA | |||
| F: GCCCTTTGTTGCTTGCG | 213 | 54 | |
| R: GGCTGATGCTGCCATCTGTG |
Figure 1The distribution of patient ages, sample types and clinic departments among 45 OS-MRSA strains. (A) ages; (B) sample types; (C) clinic departments.
Figure 2The MICs distribution of three kinds of S. aureus strains against oxacillin, cefoxitin, penicillin, vancomycin, clindamycin, and erythromycin.
MIC50 and MIC90 Values of Three Kinds of S. aureus Strains Against Oxacillin, Cefoxitin, Penicillin, Vancomycin, Clindamycin, and Erythromycin
| Antibiotics | MIC Range of ATCC29213 (μg/mL) | MSSA (n=30) | OS-MRSA (n=45) | MRSA (n=30) | |||
|---|---|---|---|---|---|---|---|
| MIC50 (μg/mL) | MIC90 (μg/mL) | MIC50 (μg/mL) | MIC90 (μg/mL) | MIC50 (μg/mL) | MIC90 (μg/mL) | ||
| Oxacillin | 0.25 | 0.38 | 0.75 | 1 | 4 | 12 | 32 |
| Cefoxitin | 2 | 2 | 2 | 4 | 16 | 32 | 32 |
| Penicillin | 0.25–0.5 | 1.5 | 32 | 2 | 32 | 32 | 32 |
| Vancomycin | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Erythromycin | 0.75 | 256 | 256 | 256 | 256 | 256 | 256 |
| Clindamycin | 0.094–0.5 | 0.5 | 256 | 0.38 | 256 | 0.75 | 256 |
Characteristics of 45 OS-MRSA Strains in the Study
| Strains | Molecular Typing | VITEK 2 Compact | Toxins | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MLST | SCC | Oxacillin MIC (μg/mL) | Cefoxitin Screening | PVL | TSST-1 | Enterotoxin | Haemolysin | Clf | ||||
| 1 | ST188 | IV | 0.5 | − | − | − | − | + | + | + | + | + |
| 2 | ST338 | IV` | 1 | − | − | − | − | + | + | + | + | + |
| 3 | ST5 | IV | 0.5 | − | − | − | − | + | + | + | + | + |
| 4 | ST398 | IV | 0.5 | − | − | − | − | − | + | + | + | + |
| 5 | ST896 | IV | ≤0.25 | − | − | − | + | + | + | + | + | + |
| 6 | ST30 | IV | ≤0.25 | − | − | + | + | − | + | + | + | + |
| 7 | ST22 | V | 0.5 | − | − | − | − | − | + | + | + | + |
| 8 | ST338 | IV | ≤0.25 | − | − | − | − | − | + | + | + | + |
| 9 | ST22 | IV | ≤0.25 | − | − | − | − | − | + | + | + | + |
| 10 | ST15 | IV | ≤0.25 | − | − | − | − | − | + | + | + | + |
| 11 | ST2290 | IV | 0.5 | − | − | − | − | − | + | + | + | + |
| 12 | ST5 | IV | ≤0.25 | − | − | − | − | − | + | + | + | + |
| 13 | ST59 | IV | 2 | + | + | + | − | − | + | + | + | + |
| 14 | ST59 | IV | 2 | + | − | − | − | + | + | + | + | + |
| 15 | ST398 | IV | 0.5 | + | − | − | − | − | + | + | + | + |
| 16 | ST59 | IV | 1 | + | − | − | − | + | + | + | + | + |
| 17 | ST59 | IV | 1 | + | − | − | − | + | + | + | + | + |
| 18 | ST398 | IV | ≤0.25 | + | − | − | − | − | + | + | + | + |
| 19 | ST338 | IV | 2 | + | − | − | − | − | + | + | + | + |
| 20 | ST25 | IV | ≤0.25 | − | − | − | − | + | + | + | + | + |
| 21 | ST96 | IV | ≤0.25 | + | + | − | − | − | + | + | + | + |
| 22 | ST30 | IV | 0.5 | − | − | − | − | − | + | + | + | + |
| 23 | ST6 | IV | ≤0.25 | − | − | − | − | − | + | + | + | + |
| 24 | ST338 | IV | 2 | + | − | − | − | − | + | + | + | + |
| 25 | ST338 | IV | 2 | + | − | − | − | − | + | + | + | + |
| 26 | ST5 | IV | 0.5 | − | − | − | − | − | + | + | + | + |
| 27 | ST338 | IV | 0.5 | − | − | − | − | + | + | + | + | + |
| 28 | ST338 | IV | 1 | + | − | − | − | + | + | + | + | + |
| 29 | ST59 | IV | 1 | + | − | − | − | − | + | + | + | + |
| 30 | ST338 | IV | 1 | + | − | − | − | − | + | + | + | + |
| 31 | ST59 | IV | 1 | + | − | − | + | + | + | + | + | + |
| 32 | ST59 | IV | 2 | + | − | − | − | + | + | + | + | + |
| 33 | ST30 | IV | ≤0.25 | − | − | + | + | + | + | + | + | + |
| 34 | ST59 | IV | 2 | + | − | − | + | + | + | + | + | + |
| 35 | N | IV | 2 | + | − | − | − | − | + | + | + | + |
| 36 | N | IV | ≤0.25 | − | − | − | − | − | + | + | + | + |
| 37 | ST 59 | IV | ≤0.25 | − | − | − | − | + | + | + | + | + |
| 38 | ST22 | IV | 4 | − | − | − | − | − | + | + | + | + |
| 39 | ST2167 | IV | 2 | + | − | − | − | − | + | + | + | + |
| 40 | ST59 | IV | 2 | + | − | − | − | + | + | + | + | + |
| 41 | ST22 | IV | 0.5 | − | − | − | − | − | + | + | + | + |
| 42 | ST5 | IV | ≤0.25 | − | − | − | − | − | + | + | + | + |
| 43 | N | IV | 1 | + | − | − | − | − | + | + | + | + |
| 44 | ST59 | IV | 2 | + | − | − | + | + | + | + | + | + |
| 45 | ST22 | IV | 4 | + | − | − | − | − | + | + | + | + |